Market Overview

UPDATE: Wells Fargo Initiates Coverage on Illumina on Prime Market Position

Related ILMN
Illumina Now A Buy Following Q2 Beat, Improved Sales Outlook
7 Biggest Price Target Changes For Monday

In a report published Tuesday, Wells Fargo Securities analyst Tim Evans initiated coverage on Illumina (NASDAQ: ILMN) with an Outperform rating.

In the report, Wells Fargo Securities noted, “We are initiating coverage of ILMN with an Outperform rating as we believe the stock is the best way for investors to achieve broad exposure to the personalized medicine revolution likely to play out over the coming decade. Illumina has positioned itself as the clear market leader in next-generation sequencing (NGS), which we believe will be the primary tool enabling the application of personalized medicine. Illumina is practically unchallenged in high-throughput sequencing and also has what we believe is the best platform in a duopoly low-throughput sequencing market. Though the risk of technological disruption is always present, we believe Illumina will be able to stay at the top of a high-growth (i.e., approximately 20%) industry. Our 2013 and 2014E EPS are $1.72 and $2.04, and our valuation range is $90-95, based on our DCF analysis (WACC = 8%; terminal NOPLAT growth = 2%), which represents 45x our 2014E PS and about 27x our 2014E EBITDA.”

Illumina closed on Monday at $79.58.

Latest Ratings for ILMN

Sep 2017ArgusMaintainsBuy
Aug 2017Canaccord GenuityUpgradesHoldBuy
Jul 2017Morgan StanleyMaintainsUnderweight

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Tim Evans Wells Fargo SecuritiesAnalyst Color Initiation Analyst Ratings


Related Articles (ILMN)

View Comments and Join the Discussion!

Partner Center